Please use this identifier to cite or link to this item:
Title: Penicillin Allergy Delabeling Program: an exploratory economic evaluation in the Australian context.
Austin Authors: Brusco, Natasha K;Bury, Susan;Chua, Kyra Y L ;Vogrin, Sara;Holmes, Natasha E ;Trubiano, Jason 
Affiliation: Department of Medicine (St Vincent's Hospital), University of Melbourne, Melbourne, Victoria, Australia
Department of Infectious Diseases and The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria
Medicine (University of Melbourne)
Alpha Crucis Group, Health Economics, Melbourne, Victoria, Australia
Rehabilitation, Ageing and Independent Living (RAIL) Research Centre, Monash University, Melbourne, Victoria, Australia
Department of Medicine and Radiology, University of Melbourne, Melbourne, Victoria
Infectious Diseases
Data Analytics Research and Evaluation (DARE) Centre
Issue Date: Jan-2023
Date: 2021-09-15
Publication information: Internal Medicine Journal 2023; 53(1): 74-83
Abstract: Internationally, clinical and economic advantages of low-risk penicillin delabeling have been explored, supporting changes to healthcare delivery systems where penicillin delabeling is embedded into inpatient usual care. To determine if economic advantages of low-risk inpatient penicillin delabeling, described in the international literature, are realised in the Australian context. This explorative economic evaluation had prospective patient data collection between January and August 2019, across two Australian health services. Part-1: Determine the cost per effectively delabeled patient for Penicillin Allergy Delabeling Program inpatients (PADP cohort) compared to Outpatient Antibiotic Allergy Testing Service outpatients (OAATS cohort). Part-2: A cost analysis to compare hospital costs for inpatients with low-risk penicillin allergy who did (PADP cohort) and did not (usual care cohort) undergo PADP delabeling. Part-1: The PADP (n=350) and OAATS (n=27 patients, n=36 individual visits) cohorts were comparable. In PADP, costs/proportion delabeled was $20.10/0.98, equating to $20.51 per effectively delabeled patient; in OAATS, it was $181.24/0.50, equating to $362. Compared to OAATS, PADP was associated with savings of $341.97 per effectively delabeled patient; indicating the outpatient testing was the dominated strategy, being more costly and less effective. Part-2: The PADP (n=218) and usual care (n=32) cohorts were comparable. Significantly favouring the delabeled PADP cohort, mean difference per patient was -4.41 days (95%CI -7.64, -1.18) and -$9,467.72 (95%CI -$15,419.98, -$3,515.46). Consistent with international literature, delabeling low-risk penicillin allergies in the inpatient setting had economic advantages in the Australian context. Fully powered economic evaluations are urgently required to consolidate these findings. This article is protected by copyright. All rights reserved.
DOI: 10.1111/imj.15532
ORCID: 0000-0002-8825-5109
Journal: Internal Medicine Journal
PubMed URL: 34523209
Type: Journal Article
Subjects: Antibiotic management
Delabeling; Antibiotics; Economic
health service research
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 30, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.